The Joint VBA Statement, prepared alongside Genetic Alliance UK, which nearly half our members signed, was submitted on Friday 12th...

Cancer52 welcomes the new additional investment of £160 million in the Cancer Drugs Fund (CDF) announced by Health Secretary Jeremy Hunt...

Please find here Cancer52's response to the NICE Methods of Technology Appraisal Consultation, which was submitted to NICE on Tuesday...

Cancer52 is delighted to announce that Clara Mackay, Deputy CEO of Pancreatic Cancer UK, has been appointed as interim chair of Cancer52....

On the basis of the increasing experience of our members with NICE Technology Appraisals Cancer52 has commented in detail on a number of...

Making sure that rare cancers aren’t written out of the script Cancer52 published its briefing paper on the UK Strategy for Rare...

Cancer52 published its briefing paper "NICE and Value Based Assessment (VBA) - NICE do it their way." NICE is due to consult on its...

The National Cancer Intelligence Network (NCIN) has published new research on Routes to Diagnosis (RtD) for 55 cancer sites or groups,...

In December 2013, Cancer52 wrote a letter to Sir John Chisholm, Executive Chair of Genomics England, expressing its alarm that the 100K...

Cancer52 had a stand at exhibition at the MacMillan Primary Care Conference in November 2013. Visitors to the stand learned of the work...